Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, has made a significant investment in its ADME (Absorption, Distribution, Metabolism and Excretion) suite of services. This investment includes expanding laboratory space, and adding new capabilities as well as a dedicated customer service team.   Celerion has invested in new equipment and laboratory space to perform on-site scintillation counting allowing for radioactivity recovery results to be delivered in re...